Antiphospholipid antibodies and hyperhomocysteinaemia in patients with vascular occlusive disease

Summary

Hyperhomocysteinemia (HHcy), lupus anticoagulant (LA) and anticardiolipin antibodies (ACA) are independent risk factors for thrombosis. Even though risks are cumulative, the clinical impact of the association is unknown. Preliminary data suggested that HHcy might be associated with transient LA and ACA, disappearing after lowering HHcy. We prospectively evaluated the association of HHcy and LA/ACA, the effect of lowering HHcy with folic acid in LA behavior, and the correlation of the initial dRVVT with LA behavior after folic acid in 210 patients with thrombosis and adverse pregnancy outcomes. Prevalence of HHcy among patients with LA/ACA was 40%. Thirty-one patients exhibited only HHcy (15%; Group 1), 106 (50%; Group 2) had only LA/ACA, while 73 (35%; Group 3) had both. After therapy, 63% and 64% of LA/ACA remained positive in Group 3 and 2, respectively. We observed a trend towards a more positive dRVVT in persistent LA after lowering HHcy. No differences in clinical presentation or in outcomes after two years of followup were observed among the groups. Even though the association of HHcy and LA/ACA is common in patients with thrombosis, it might have no prognostic implications if Hcy levels are lowered. Currently, no laboratory findings correlate with LA behavior, which is independent of homocysteine levels and vitamin treatment.

Keywords

Clinical / epidemiological studies - homocysteine - antiphospholipid antibodies - deep vein thrombosis - cerebrovascular disease

• References

• 1 Wilson WA, Gharavi AE, Koike T. et al. International consensus statement on preliminary classification criteria for definite Antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
• 2 Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis 2003; 62: 388-93.
• 3 Levine JS, Branch DW, Rauch J. The Antiphospholipid syndrome. N Engl J Med 2002; 346: 752-63.
• 4 Meroni PL, Borghi MO, Raschi E. et al. Inflammatory response and the endothelium. Thromb Res 2004; 114: 329-34.
• 5 Aguilar B, Rojas JC, Collados MT. Metabolism of homocysteinaemia and its relationship with cardiovascular disease. J Thromb Thrombolysis 2004; 18: 75-87.
• 6 den Heijer M, Koster T, Blom HJ. et al. Hyperhomocysteinaemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-62.
• 7 Das UN. Folic acid says NO to vascular diseases. Nutrition 2003; 19: 686-92.
• 8 Galli M, Luciani D, Bertolini G. et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-32.
• 9 Lentz SR. Mechanisms of homocysteinaemia-induced atherothrombosis. J Thromb Haemost 2005; 03: 1646-54.
• 10 Avivi I, Lanir N, Hoffman R. et al. Hyperhomocysteinaemia is common in patients with antiphospholipid syndrome and may contribute to expression of major thrombotic events. Blood Coagul Fibrinolysis 2002; 13: 169-72.
• 11 Kassis J, Neville C, Rauch J. et al. Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinaemia in arterial thrombosis. Thromb Haemost 2004; 92: 1312-9.
• 12 Ames PR, Margaglione M, Tommasino C. et al. Impact of plasma homocysteinaemia and prothrombin G20210 A on primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 2001; 12: 699-704.
• 13 Seriolo B, Fasciolo D, Sulli A. et al. Homocysteinaemia and antiphospholipid antibodies in rheumatoid arthritis patients: relationships with thrombotic events. Clin Exp Rheumatol 2001; 19: 561-4.
• 14 Martinez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV. et al. Homocysteinaemia, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus 2004; 13: 927-33.
• 15 McIntyre JA. The appearance and disappearance of antiphospholipid autoantibodies subsequent to oxidation-reduction reactions. Thromb Res 2004; 114: 579-87.
• 16 Casais P, Alberto MF, Gennari LC. et al. Antiphospholipid antibodies and Hyperhomocysteinemia: response to therapy with folic acid. Journal of Thrombosis and Haemostasis. 2003 01. Suppl 1: Abstr P0421.
• 17 Brandt JT, Triplett DA, Alving B. et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on lupus anticoagulant/ antiphospholipid antibody of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 1185-90.
• 18 Galli M. Antiphospholipid antibodies and thrombosis: do test patterns identify the patients’ risk?. Thromb Res 2004; 114: 597-601.